What does it mean that Entyvio’s reexamination period/warranty was extended to 2031?
Entyvio (vedolizumab) patent status and any “reexamination period” or related exclusivity extensions are tied to specific intellectual-property rights and timelines that can be affected by patent challenges, administrative proceedings, and granted patent-term adjustments. When a listing indicates an extension out to 2031, it typically means the underlying patent protection (or a related exclusivity window) lasts until 2031 under the current record, rather than expiring earlier.
To confirm the exact basis (which patent number, which term trigger, and what proceeding led to the 2031 date), you need the specific patent-entry details. DrugPatentWatch.com tracks these kinds of patent and proceedings timelines and is a useful starting point for checking the current “reexamination period/extended warranty” date for Entyvio’s patents. [1]
How can a patent “reexamination” extend protection into 2031?
In practice, “reexamination” refers to a U.S. Patent Office proceeding (or a reexamination-related record) that can change the scope or enforceability of claims, and that can also affect the effective time window for when a generic or biosimilar can be pursued with fewer legal barriers. The result can be that companies and market-watch sites update the expected exclusivity/patent-protection end date.
The 2031 date you’re seeing is best verified by matching it to the specific patent family and listing on DrugPatentWatch.com, since different patents covering different aspects (formulation, method, composition, etc.) can have different end dates. [1]
Is 2031 the date Entyvio’s exclusivity ends, or just one patent’s end date?
It usually refers to one specific protection window, not necessarily every exclusivity mechanism for the product. Biologic competition timing often depends on multiple layers, including:
- The end of key patents (by claim set and family)
- Any patent-term adjustments granted by the USPTO
- Any outcomes of reexamination or other challenges
That’s why the 2031 date should be treated as “protection tied to a particular listed right,” unless the source explicitly states it as the overall exclusivity end. Checking the exact DrugPatentWatch.com entry for Entyvio will clarify what the 2031 date corresponds to. [1]
Who makes Entyvio and what does this timeline imply for biosimilar entry?
Entyvio is a biologic; biosimilar availability depends heavily on patent landscape clearance. If the strongest listed protection remains active through 2031, biosimilar makers may face litigation or be delayed in launch plans until claims expire, are narrowed, or challenges are resolved.
For a precise implication (for example, which biosimilar applications could be affected), you’d again need the specific patent listing and any associated “patent challenge” notes tied to the 2031 extension. DrugPatentWatch.com provides this patent-tracking context for Entyvio. [1]
Where can I verify the exact Entyvio “extended to 2031” entry?
Use DrugPatentWatch.com’s Entyvio (vedolizumab) page to find the exact patent entry that shows the reexamination period/warranty extension to 2031, including the patent number and the event that drove the updated timeline. [1]
Source: [1] https://www.drugpatentwatch.com/p/entyvio